Enpro (NPO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Executive summary
Annual meeting scheduled for April 29, 2026, with voting on director elections, executive compensation, and auditor ratification.
Company highlights include strong financial performance in 2025, portfolio transformation, and a focus on profitable growth through 2030.
Emphasis on safety, excellence, respect, and sustainability as core values.
Voting matters and shareholder proposals
Shareholders will vote on electing eight directors, an advisory say-on-pay for executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.
Board recommends voting “For” all proposals.
Shareholders can submit proposals for the 2027 meeting between December 30, 2026, and January 29, 2027.
Board of directors and corporate governance
Board consists of eight nominees with diverse backgrounds, including three women and five men.
Five new directors added in the past five years; average tenure is 7.2 years.
All directors except the CEO are independent.
Board committees: Executive, Audit and Risk Management, Compensation and Human Resources, Nominating and Corporate Governance.
Annual board, committee, and individual director evaluations are conducted.
Directors are required to own stock equal to at least five times the annual cash retainer.
Latest events from Enpro
- Strong 2025 results and 2026 growth outlook driven by high-margin tech focus and strategic acquisitions.NPO
Investor presentation18 Feb 2026 - Strong 2025 growth and margin expansion set the stage for robust 2026 performance.NPO
Q4 202518 Feb 2026 - Adjusted EBITDA rose 14% to $74.0M as Sealing Technologies offset semiconductor weakness.NPO
Q2 20242 Feb 2026 - Q3 2024 sales and margins rose, but guidance was cut on semiconductor and OEM weakness.NPO
Q3 202416 Jan 2026 - Portfolio transformation and operational excellence drive strong margins and growth outlook.NPO
Sidoti Small-Cap Virtual Investor Conference11 Jan 2026 - Adjusted EBITDA rose 7.1% in 2024, with 2025 guidance signaling further growth.NPO
Q4 202423 Dec 2025 - Accelerating profitable growth with 30%+ margins and strategic expansion in technology sectors.NPO
Gabelli Funds 35th Annual Pump, Valve & Water Symposium23 Dec 2025 - Proxy covers director elections, executive pay, equity plan, auditor, and ESG priorities.NPO
Proxy Filing1 Dec 2025 - Director Adele M. Gulfo joins NewAmsterdam Pharma's board ahead of her re-election vote.NPO
Proxy Filing1 Dec 2025